DE3782440D1 - Verfahren und ausruestung zur herstellung von radioaktivmarkierten antikoerpern fuer die in-vivo-krebsdiagnose und therapie. - Google Patents

Verfahren und ausruestung zur herstellung von radioaktivmarkierten antikoerpern fuer die in-vivo-krebsdiagnose und therapie.

Info

Publication number
DE3782440D1
DE3782440D1 DE8787200081T DE3782440T DE3782440D1 DE 3782440 D1 DE3782440 D1 DE 3782440D1 DE 8787200081 T DE8787200081 T DE 8787200081T DE 3782440 T DE3782440 T DE 3782440T DE 3782440 D1 DE3782440 D1 DE 3782440D1
Authority
DE
Germany
Prior art keywords
therapy
equipment
cancer diagnosis
vivo cancer
radioactively marked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787200081T
Other languages
English (en)
Other versions
DE3782440T2 (de
Inventor
Erfinder Wird Nachtraeglich Benannt Der
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhomed Inc
Original Assignee
Rhomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27124608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3782440(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhomed Inc filed Critical Rhomed Inc
Publication of DE3782440D1 publication Critical patent/DE3782440D1/de
Application granted granted Critical
Publication of DE3782440T2 publication Critical patent/DE3782440T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
DE8787200081T 1986-01-24 1987-01-20 Verfahren und ausruestung zur herstellung von radioaktivmarkierten antikoerpern fuer die in-vivo-krebsdiagnose und therapie. Expired - Fee Related DE3782440T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82199986A 1986-01-24 1986-01-24
US06/849,741 US4940670A (en) 1986-01-24 1986-04-09 Method for compounding and testing patient specific monoclonal antibodies and monoclonal antibody fragments for in vivo use

Publications (2)

Publication Number Publication Date
DE3782440D1 true DE3782440D1 (de) 1992-12-10
DE3782440T2 DE3782440T2 (de) 1993-04-08

Family

ID=27124608

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787200081T Expired - Fee Related DE3782440T2 (de) 1986-01-24 1987-01-20 Verfahren und ausruestung zur herstellung von radioaktivmarkierten antikoerpern fuer die in-vivo-krebsdiagnose und therapie.

Country Status (5)

Country Link
US (1) US4940670A (de)
EP (1) EP0234612B1 (de)
AU (1) AU6785987A (de)
CA (1) CA1305919C (de)
DE (1) DE3782440T2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004910A1 (en) * 1990-09-11 1992-04-02 The Regents Of The University Of California Na-k-atpase inhibiting natriuretic substances
US6660233B1 (en) 1996-01-16 2003-12-09 Beckman Coulter, Inc. Analytical biochemistry system with robotically carried bioarray
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US7612020B2 (en) 1998-12-28 2009-11-03 Illumina, Inc. Composite arrays utilizing microspheres with a hybridization chamber
CA2328356A1 (en) * 1999-12-22 2001-06-22 Itty Atcravi Recreational vehicles
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
US6709655B2 (en) * 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US20050031619A1 (en) * 2001-03-21 2005-02-10 Nicodemus Christopher F. Therapeutic compositions that alter the immune response
WO2003000176A2 (en) * 2001-06-20 2003-01-03 Molecular Staging, Inc. Conjugates of reduced antibodies and biomolecules
CA2481796A1 (en) * 2002-04-11 2003-10-23 Altarex Medical Corporation Binding agents and their use in targeting tumor cells
US7335759B2 (en) * 2002-12-02 2008-02-26 Universidad Nacional Autónoma de Méxica (UNAM) Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
MXPA06000965A (es) * 2003-07-25 2007-05-04 Silanes Sa De Cv Lab Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
WO2005038055A1 (en) * 2003-09-22 2005-04-28 Nathaniel Tue Tran Multiplexing array techniques
AU2005258014B2 (en) * 2004-06-17 2012-07-12 Mannkind Corporation Tumor-associated antigen profiles in cancer diagnostics and immunotherapy
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
EP1863908B1 (de) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transkription und amplifikation von rna bei simultaner degradierung von dna
US20060246576A1 (en) 2005-04-06 2006-11-02 Affymetrix, Inc. Fluidic system and method for processing biological microarrays in personal instrumentation
US7381802B2 (en) * 2005-04-15 2008-06-03 Universidad Nacional Autónoma De México (UNAM) Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
EP1762627A1 (de) 2005-09-09 2007-03-14 Qiagen GmbH Verfahren zur Aktivierung einer Nukleinsäure für eine Polymerase-Reaktion
DE102008002715A1 (de) 2008-06-27 2009-12-31 Evonik Röhm Gmbh 2-Hydroxyisobuttersäure produzierende rekombinante Zelle
GB0900425D0 (en) * 2009-01-12 2009-02-11 Ucb Pharma Sa Biological products
CA2760774A1 (en) 2009-05-05 2010-11-11 Altermune Technologies, Llc Chemically programmable immunity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017597A (en) * 1974-10-30 1977-04-12 Monsanto Company Unitized solid phase immunoassay kit and method
US4090920A (en) * 1976-02-19 1978-05-23 Fisher Scientific Company Disposable antibiotic susceptability test package
AT343822B (de) * 1976-08-20 1978-06-26 Immuno Ag Radioimmunologisches verfahren und einrichtung zur bestimmung von antigenen
US4225575A (en) * 1978-05-15 1980-09-30 Ventrex Laboratories, Inc. Method and apparatus for performing in vitro clinical diagnostic tests using a solid phase assay system
US4294817A (en) * 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4378344A (en) * 1979-09-28 1983-03-29 Ventrex Laboratories, Inc. Method and apparatus for performing multiple, simultaneous in vitro diagnostic tests using a solid phase system
US4540659A (en) * 1981-04-17 1985-09-10 Syva Company Simultaneous calibration heterogeneous immunoassay
US4713352A (en) * 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
GB2147698B (en) * 1981-11-17 1986-05-08 Unilever Plc Test apparatus for immunoassay
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
EP0087898A1 (de) * 1982-02-22 1983-09-07 Cancer Research Campaign Technology Limited Antikörper und Antigene zur Bestimmung und Behandlung von Krebs
DE3382548D1 (de) * 1982-03-03 1992-05-27 Becton Dickinson Co Trageplatte und anordnung fuer immunologische untersuchungen.
EP0106855A1 (de) * 1982-04-16 1984-05-02 Genefusion S.A. Vorrichtung zur analyse von biologischen proben
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
FI860249A (fi) * 1985-02-28 1986-08-29 Becton Dickinson Co Apparat och foerfarande foer flerfaldigt, samtidigt prov.
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy

Also Published As

Publication number Publication date
AU6785987A (en) 1987-07-30
EP0234612B1 (de) 1992-11-04
US4940670A (en) 1990-07-10
DE3782440T2 (de) 1993-04-08
EP0234612A1 (de) 1987-09-02
CA1305919C (en) 1992-08-04

Similar Documents

Publication Publication Date Title
DE3782440D1 (de) Verfahren und ausruestung zur herstellung von radioaktivmarkierten antikoerpern fuer die in-vivo-krebsdiagnose und therapie.
DE3782972T2 (de) Ic-karte und verfahren zur herstellung derselben.
DE3583576D1 (de) Kuenstliches blutgefaess und verfahren zur herstellung.
DE3764253D1 (de) Medizinischer saugkoerper mit roentgenkontrastmittel und verfahren zu seiner herstellung.
AT373531B (de) Verbundkoerper sowie verfahren und vorrichtung zu seiner herstellung
DE3888177D1 (de) Schnellauflösbare arzneimitteldosierungseinheit sowie verfahren zur herstellung.
DE3879218D1 (de) Medizinisches instrument und verfahren zur herstellung.
DE69012592T2 (de) Verfahren zur Hautbehandlung.
DE3784381D1 (de) Verfahren und vorrichtung zur herstellung von brot.
DE68905331D1 (de) Scharfes medizinisches werkzeug und verfahren fuer seine herstellung.
DE3783396T2 (de) Verfahren zur herstellung von bishomo-gamma-linolensaeure und eicosapentaensaeure.
DE3788184D1 (de) Zahnärztliche Röntgendiagnostikeinrichtung zur Herstellung von Übersichtsaufnahmen von im Schädel verlaufenden Schichten.
AT366907B (de) Zahnpflegemittel sowie verfahren zur herstellung des schleifmittels derselben
DE3583875D1 (de) Verfahren zur herstellung von kugelfoermigen vollblut-erythrocyten und fixierung derselben.
DE3784518T2 (de) Medizinisches material und verfahren zur herstellung.
DE69007418D1 (de) Octadienyläther und verfahren zur herstellung von octadienyläthern.
ATA232687A (de) Zahnpflegemittel, sowie verfahren zur herstellung des zahnpflegemittels
DE3781923T2 (de) Verfahren und vorrichtung zur herstellung von heissem eisenschwamm.
DE3684922D1 (de) Verfahren zur herstellung von 2-phenylbenzotriazolen und 2-phenylbenzotriazol-n-oxyden.
DE3885304T2 (de) Zubereitung für zahnbehandlung und verfahren zur herstellung.
ATA200786A (de) Skischuh und verfahren zur herstellung desselben
DE3783480D1 (de) Verfahren und vorrichtung zur herstellung von schieberkernen.
DE3765855D1 (de) Dimethylphenylsilylmethylpolysilan und verfahren zur herstellung desselben.
ATE82075T1 (de) Verfahren und ausruestung zur herstellung von radioaktivmarkierten antikoerpern fuer die in-vivo- krebsdiagnose und therapie.
DE3574974D1 (de) Verfahren zur herstellung von milbemycinderivaten und einige in diesem verfahren verwendete derivate.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8339 Ceased/non-payment of the annual fee